hydroxychloroquine

hydroxychloroquine
Name	Hydroxychloroquine
Class	Antimalarial, disease-modifying antirheumatic drug
Routes of administration	Oral
Metabolism	Hepatic
Excretion	Renal

hydroxychloroquine Hydroxychloroquine is an oral antimalarial and immunomodulatory medication used in the treatment of several chronic inflammatory and infectious diseases. It is chemically related to chloroquine and has been the subject of clinical, regulatory, and public debate involving multiple governments and health agencies. Major manufacturers, professional societies, and investigative commissions have evaluated its safety and efficacy across a range of indications.

Pharmacology

Hydroxychloroquine is a 4-aminoquinoline derivative whose pharmacokinetics involve absorption in the gastrointestinal tract and distribution to tissues including liver, spleen, lung, and retina; these properties were characterized in comparative studies involving agents such as quinine and mefloquine. Drug interaction profiles were assessed in trials coordinated by organizations such as the World Health Organization and regulatory agencies like the Food and Drug Administration and European Medicines Agency; coadministration considerations include therapies studied in trials alongside azithromycin and agents evaluated in pandemic responses by Centers for Disease Control and Prevention. Metabolic pathways involve hepatic enzymes referenced in pharmacology texts used at institutions such as Johns Hopkins University and Mayo Clinic, and elimination kinetics were described in early pharmacokinetic reports from research centers including Oxford University and Karolinska Institutet. Formulation stability, generic manufacturing, and supply chain analyses have been investigated by corporations listed on exchanges like the New York Stock Exchange and regulatory inspections by agencies from countries including India and Brazil.

Medical Uses

Hydroxychloroquine has been established for prophylaxis and treatment of malaria species such as those studied during expeditions led by Sir Ronald Ross and was adopted into rheumatology practice for autoimmune conditions cited in guidelines from organizations like the American College of Rheumatology and European League Against Rheumatism. Indications include management of systemic lupus erythematosus and rheumatoid arthritis as described in clinical trials published in journals from publishers such as The Lancet and The New England Journal of Medicine; treatment algorithms reference consensus statements from bodies like the American Academy of Dermatology and the British Society for Rheumatology. Off-label and investigational uses were explored in platforms coordinated by World Health Organization solidarity trials and national task forces in countries such as France and China, with randomized studies conducted at centers including Massachusetts General Hospital and Wuhan Union Hospital.

Adverse Effects and Safety

Safety profiles include ocular toxicity leading to retinopathy first characterized in reports associated with ophthalmology departments at institutions like Moorfields Eye Hospital and Bascom Palmer Eye Institute; screening recommendations were promulgated by specialty groups such as the American Academy of Ophthalmology. Cardiotoxicity, including conduction disorders and arrhythmias, was documented in case series reviewed by cardiovascular societies like the American College of Cardiology and European Society of Cardiology particularly when used with agents such as azithromycin and in settings monitored by critical care units at hospitals like Bellevue Hospital and Cleveland Clinic. Dermatologic, neuromuscular, and hematologic adverse events were reported in pharmacovigilance databases maintained by regulators such as the Medicines and Healthcare products Regulatory Agency and the Pharmaceuticals and Medical Devices Agency of Japan.

Mechanism of Action

Proposed mechanisms include interference with endosomal acidification and lysosomal function, effects on antigen presentation observed in immunology laboratories at institutions like Max Planck Society and Harvard Medical School, and modulation of toll-like receptor signaling pathways studied by researchers affiliated with institutes such as the National Institutes of Health and Pasteur Institute. Antiviral hypotheses were generated from in vitro studies from laboratories at National University of Singapore and University of Hong Kong, while immunomodulatory effects underpin therapeutic use in autoimmune disorders as discussed in reviews from universities including Stanford University and University College London.

History and Development

Derivation from quinoline compounds traces back to antimalarial chemistry developed in the era of researchers like Paul Ehrlich and pharmaceutical programs at firms later known as Bayer and Roche. Clinical adoption followed trials and wartime use chronicled in historical reviews from archives at institutions such as the Wellcome Library and National Library of Medicine. Regulatory approvals and label changes over decades were managed by agencies including the Food and Drug Administration and national ministries of health in countries such as United Kingdom and Canada, while generic production expanded through manufacturers in regions like Southeast Asia and Latin America.

Controversies and Public Health Issues

The medication became prominent in public discourse during infectious disease outbreaks, sparking policy debates involving political leaders and agencies such as the White House, European Commission, and national public health institutes; high-profile advocacy, media coverage, and legislative inquiries engaged stakeholders including academic authors in journals like Science and Nature. Randomized trials and meta-analyses by consortia associated with Cochrane and large clinical networks produced evidence that shaped recommendations from World Health Organization and national advisory committees, while supply shortages and allocation decisions prompted responses from NGOs such as Doctors Without Borders and health ministries in countries like India and Brazil. Legal, ethical, and communication controversies involved scientific journals, regulatory appeals, and public demonstrations addressed by organizations including the International Committee of Medical Journal Editors and courts in multiple jurisdictions.

Category:Antimalarial agents